A randomized phase 2 trial of 28-day (Arm A) versus 14-Day (Arm B) schedule of venetoclax plus azacitidine in newly diagnosed acute myeloid leukemia patients ≥ 60 years Meeting Abstract
| Authors: | Borate, U. M.; Huang, Y.; Johnson, M. F.; Zeidner, J. F.; Swords, R. T.; Koenig, K. L.; Stein, E. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; Olin, R.; Blum, W.; Schiller, G. J.; Lin, T. L.; Redner, R. L.; Curran, E. K.; Heerema, N. A.; Martycz, M.; Rosenberg, L.; Marcus, S. G.; Chen, T.; Stefanos, M.; Levine, R. L.; Druker, B. J.; Yocum, A. O.; Burd, A.; Mims, A.; Byrd, J. C. |
| Abstract Title: | A randomized phase 2 trial of 28-day (Arm A) versus 14-Day (Arm B) schedule of venetoclax plus azacitidine in newly diagnosed acute myeloid leukemia patients ≥ 60 years |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 1535 |
| Language: | English |
| ACCESSION: | WOS:001159306706006 |
| DOI: | 10.1182/blood-2023-187383 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work